首页
返回
在含蒽环类药物免疫化疗联合利妥昔单抗疗法出现之前，原始国际预后指数（IPI）已建立并得到验证。临床试验已证实利妥昔单抗可以提供弥漫大B细胞淋巴瘤患者的生存率。
修订的国际预后指数（R-IPI）被建立用于预测接受化疗联合利妥昔单抗治疗者的结局。该评分能将患者分为三组（预后极好、预后良好、预后差），在新疗法时期，三组患者生存率均>50%。
The original IPI was developed by Shipp et al. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987-994.
The newer prognostic index was revised/developed by Sehn et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.